New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease-Reference-Cited by-同舟云学术

New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease

Published:2016-05-26 Issue:7 Volume:18 Page:
ISSN:1522-6417
Container-title:Current Hypertension Reports
language:en
Short-container-title:Curr Hypertens Rep

Author:

Rastogi Anjay,Arman Farid,Alipourfetrati Setareh

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11906-016-0663-4.pdf

Reference94 articles.

1. Heyeraas KJ, Aukland K. Interlobular arterial resistance: influence of renal arterial pressure and angiotensin II. Kidney Int [Internet]. 1987;31(6):1291–8. doi: 10.1038/ki.1987.142 .

2. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens [Internet]. 2007;21(1):20–7. doi: 10.1038/sj.jhh.1002101 .

3. Zahradka P. NF-kB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol [Internet]. 2002;34(12):1609–21. Available from: http://www.sciencedirect.com/science/article/pii/S0022282802921115 .

4. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl [Internet]. 2005;68(99):S57–65. doi: 10.1111/j.1523-1755.2005.09911.x .

5. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int [Internet]. 2004;66(1):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15200407 .

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Reactions in Renal Function and Electrolytes Associated with Antihypertensive and Antidiabetic Therapy;Blood Pressure Disorders in Diabetes Mellitus;2023

2. Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria;Mayo Clinic Proceedings;2022-11

3. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent;Expert Review of Clinical Pharmacology;2021-07-06

4. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program;Clinical Kidney Journal;2020-09-02

5. Potassium Binders for Hyperkalemia in Chronic Kidney Disease—Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis;Mayo Clinic Proceedings;2020-02